Renalytix AI And AstraZeneca Collaborate To Improve Chronic Kidney Disease Outcomes
The companies will launch "precision medicine strategies" for chronic disease that use Renalytix' AI-enabled IVDs.
You may also be interested in...
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the fourth day of the meeting.
The American Diabetes Association and Renalytix will develop a comprehensive interprofessional risk-informed Diabetes Kidney Care Pathway and Model for optimal clinical treatment and risk reduction that can be applied nationally.
During Q3 biopharmas reached $41.7bn in merger and acquisition value and drew in $44.4bn in potential deal value from alliances. Device company M&A values reached $17.9bn while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.